Programme de radioligandthérapie prostatique Lutétium-177 PSMA avec TEP PSMA

• Thérapie au lutétium-177
• Consultation avec un médecin
• Des analyses de sang
• Examen de suivi

• Transfert aéroport-clinique-aéroport

Lutetium-177 PSMA Prostate Radioligand Therapy Program with PSMA PET

The Lutetium-177 (Lu-177) PSMA Radioligand Therapy Program with PSMA PET is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program integrates molecular imaging and radioligand therapy within a structured and carefully monitored treatment pathway.

This treatment utilizes Lutetium-177, a beta-emitting radioisotope attached to a PSMA-targeting molecule that binds specifically to prostate cancer cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, resulting in controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it enables effective treatment of tumor lesions while maintaining an established and favorable safety profile.

Before treatment, a specialized PSMA PET/CT scan is performed at our hospital to confirm adequate PSMA receptor expression and evaluate disease distribution. Only patients who meet these molecular criteria are selected for Lutetium-177 PSMA therapy, ensuring an individualized and precisely targeted treatment approach.

The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols.

The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance.

Included Services

• Nuclear medicine consultation
• Blood tests (kidney, liver, hematologic profile)
• PSMA PET/CT scan for therapy eligibility assessment
• MAG-3 renal scintigraphy (first cycle only, if clinically indicated)
• Lutetium-177 PSMA treatment administration
• Post-treatment scan
• Medical follow-up by nuclear medicine specialist
• Verification of residual radioactivity for flight compatibility

The recommended stay is approximately four days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety.

For patient comfort and convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure a smooth and well-organized treatment experience.

• Coordinateur médical personnel
• Organisation de voyage médical — réservation des tickets de vol et des chambres d'hôtel à des prix réduits pour les partenaires
• Prise en charge du patient lors d'un voyage médical